Edition:
United Kingdom

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

3.90USD
12 Oct 2018
Change (% chg)

$0.18 (+4.84%)
Prev Close
$3.72
Open
$3.78
Day's High
$3.94
Day's Low
$3.75
Volume
11,566
Avg. Vol
19,139
52-wk High
$13.30
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

Trillium Therapeutics Says As Of June 30, 2018, Had Cash, Cash Equivalents & Marketable Securities, Working Capital Of $64.7 Mln & $53.4 Mln
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.TRILLIUM THERAPEUTICS - AS OF JUNE 30, 2018, HAD CASH,CASH EQUIVALENTS & MARKETABLE SECURITIES, WORKING CAPITAL OF $64.7 MILLION & $53.4 MILLION, RESPECTIVELY.  Full Article

Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Co's Common Shares By Selling Shareholders
Wednesday, 16 May 2018 

May 16 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF 2.35 MILLION CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING.  Full Article

Trillium Therapeutics Reports Annual 2017 Financial And Operating Results
Friday, 9 Mar 2018 

March 9 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS REPORTS ANNUAL 2017 FINANCIAL AND OPERATING RESULTS.TRILLIUM THERAPEUTICS - AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $81.8 MILLION.  Full Article

Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Trillium Therapeutics Inc ::MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Trillium announces private placement to fund development of cancer drugs
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Trillium Therapeutics Inc -:Trillium announces private placement.Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​.Trillium Therapeutics - ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​.Trillium Therapeutics Inc - ‍subscription agreements for offering at a price of U.S.$8.50 per share.  Full Article

Trillium Therapeutics reports Q3 results
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Trillium Therapeutics Inc :Trillium Therapeutics reports third quarter 2017 financial and operating results.Trillium Therapeutics Inc - ‍Cash and marketable securities of $64.3 million at September 30, 2017​.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article